Company news

SeaStar Medical Holding Corporation news in 2025

SeaStar Medical Holding Corporation's news releases, calls and decks from 2025, newest first.

View company

SeaStar Medical Announces 1-for-10 Reverse Split

December 23, 2025

SeaStar Medical Announces FDA Approval of Reduction in Mandatory Enrollment for SAVE Surveillance Registry Evaluating QUELIMMUNE™ Safety for Pediatric AKI

December 2, 2025

SeaStar Medical to Present at Upcoming NobleCon21 Investor Conference

November 20, 2025

SeaStar Medical Announces Appointment of Michael Messinger as CFO

November 17, 2025

SeaStar Medical Reports Third Quarter 2025 Financial Results and Provides Business Updates

November 13, 2025

SeaStar Medical to Report Third Quarter Financial Results on November 13, 2025

November 5, 2025

SeaStar Medical Reports Positive Early Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) at the 5th International Symposium on Acute Kidney Injury in Children

September 29, 2025

SeaStar Medical Reports DSMB Recommendation to Continue the NEUTRALIZE-AKI Pivotal Trial in Adult Acute Kidney Injury

September 24, 2025

SeaStar Medical to Present Early SAVE Registry Data of QUELIMMUNE in Pediatric Acute Kidney Injury at the 5th International Symposium on Acute Kidney Injury in Children

September 23, 2025

SeaStar Medical to Participate in the HC Wainwright 27th Annual Global Investment Conference

September 4, 2025

SeaStar Medical Announces Newly Published QUELIMMUNE Health Economic Study Projecting Significantly Reduced Health Care Costs in the Treatment of Pediatric AKI due to Estimated Shorter Hospital Stays and Increased Survival

September 2, 2025

SeaStar Medical Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 13, 2025

SeaStar Medical to Report Second Quarter Financial Results on August 13, 2025

August 7, 2025

SeaStar Medical Reaches New Enrollment Milestone in NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury (AKI)

August 6, 2025

SeaStar Medical Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

July 31, 2025

SeaStar Medical Reports Positive Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) from the First 20 SAVE Surveillance Registry Patients

July 22, 2025

SeaStar Medical Grows Customer Base and Expands QUELIMMUNE Surveillance Registry

July 16, 2025

SeaStar Medical Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

July 10, 2025

SeaStar Medical Expands QUELIMMUNE Adoption for Critically Ill Pediatric Patients with Acute Kidney Injury (AKI)

July 8, 2025

SeaStar Medical Announces Positive Nasdaq Listing Determination

July 2, 2025

SeaStar Medical Reports Update on Nasdaq Listing Status

June 25, 2025

SeaStar Medical Announces Two Feature Stories on QUELIMMUNE Adoption and Patient Testimonial of Life-Saving Therapy

June 24, 2025

SeaStar Medical Announces Pricing of Up to $8 Million Public Offering

June 20, 2025

AREVA Institute and SeaStar Medical Announce DoD Award of Prestigious Military Grant to AREVA Institute to Evaluate SeaStar Medical’s SCD Therapy to Advance Breakthrough Burn and Sepsis Research

June 11, 2025

SeaStar Medical Announces CMS Coverage for Medicare and Medicaid Eligible Patients with Cardiorenal Syndrome Awaiting LVAD in Investigational Trial of SCD Therapy

May 28, 2025

SeaStar Medical Reports First Quarter 2025 Financial Results and Provides Business Updates

May 14, 2025

SeaStar Medical Reaches Interim Enrollment Target for NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury

May 13, 2025

SeaStar Medical to Report First Quarter Financial Results on May 14, 2025

May 7, 2025

SeaStar Medical Announces CEO Interview on Benzinga All Access to Occur Today at Approximately 10: 50 am Eastern Time

April 30, 2025

FDA Grants SeaStar Medical Two New Breakthrough Device Designations for SCD Therapy to Treat Systemic Inflammatory Response in Adult and Pediatric Patients Undergoing Cardiac Surgery

April 8, 2025

SeaStar Medical Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

March 27, 2025

SeaStar Medical to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

March 24, 2025

SeaStar Medical Announces $6 Million Registered Direct Offering Priced At-the-Market

January 30, 2025

SeaStar Medical Adds Fifth Hospital Customer for QUELIMMUNE

January 26, 2025

SeaStar Medical Activates 15th Site for its Adult Acute Kidney Injury Pivotal Trial

January 21, 2025

FDA Approves Feasibility Study with SeaStar Medical’s Selective Cytopheretic Device in Adults with Cardiorenal Syndrome

January 12, 2025

SeaStar Medical Begins Shipping QUELIMMUNE to a Fourth Hospital Customer

January 7, 2025

Calls in 2025

Decks in 2025